Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Girvan, R. C. et al. MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity. Vaccine 29, 545–557 (2011).
2. Luckey, A., Anderson, T. J. & Silverman, M. H. A phase II, open-label, dose escalation of intravenous (IV) MIS416 in progressive multiple sclerosis. Mult Scler J 18, 516–516 (2012).
3. Luckey, A. M., Anderson, T., Silverman, M. H. & Webster, G. Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical 1, 1–12, https://doi.org/10.1177/2055217315583385 (2015).
4. White, M., Webster, G., O’Sullivan, D., Stone, S. & La Flamme, A. C. Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis. PLoS One 9, e87712 (2014).
5. Ferber, I. A. et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). The Journal of Immunology 156, 5–7 (1996).
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献